MedPath

Pilot Study to standardize the surgical management of node negative groins in penile cancer patients.

Phase 2
Conditions
Health Condition 1: C609- Malignant neoplasm of penis, unspecifiedHealth Condition 2: C609- Malignant neoplasm of penis, unspecified
Registration Number
CTRI/2019/12/022248
Lead Sponsor
Tata Memorial Centre
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Inclusion criteria

1.Age: Adult patients between 18 yrs and 70 years of age.

2.All patients should have histologically proven penile cancer and clinically normal groins bilaterally. If surgery for primary has been already done the histopathological T stage and grade of tumor should be known. If surgery for primary has not been done the grade of tumor as reported on biopsy and T stage as assessed clinically should be known.

3.Patient should have intermediate (T1G2) or high risk disease (any T G3, T or higher with any G , presence of LVI)

4.Patients should have no nodes in groin clinically palpable or seen on USG .The clinical assessment will be done by one of the investigators from surgical oncology department.

5.No evidence of distant metastasis including para-aortic nodal metastasis.

6.KPS >= 70

7.No major co morbidities preventing radical treatment

8.Signed study specific consent form

9.Adequate hepatic, renal and hematologic parameters

Exclusion Criteria

1.Low risk primary disease(Tis,Ta, T1G1)

2.Previous groin surgery

3.Uncontrolled diabetes or hypertension

4.Uncontrolled cardiac or respiratory co morbidity

5.Patient unwilling and reliable for follow up and QoL

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To assess sensitivity of DSNB in detecting sentinel lymph nodes in penile cancerTimepoint: 24 hours
Secondary Outcome Measures
NameTimeMethod
To assess the rate of complications among the patients undergoing the <br/ ><br>procedures.Timepoint: 24 hours;To assess the rate of false negatives of DSNBTimepoint: 24 hours
© Copyright 2025. All Rights Reserved by MedPath